Four companies completed Phase 3 trials for psilocybin in depression. The global therapeutic market is now projected to exceed $5 billion within a decade, driven by over forty active FDA trials and a surge in venture capital.
Key Takeaways
- Phase 3 trials for psilocybin in depression completed by 4 companies in 2023.
- Over $500 million raised by psychedelic biotechs in 2021 alone.
- The global psychedelics market was valued at $4.6 billion in 2023 and is expected to reach $12.6 billion by 2032, growing at a CAGR of 11.8%.
- Colorado legalized psilocybin therapy for adults 21+ in 2022 via Prop 122.
- 14 million Americans used psychedelics lifetime per 2023 NSDUH.
Psychedelic research and investment are accelerating rapidly, signaling growing momentum and mainstream interest worldwide.
Related reading
01 · Category
Clinical Research20 stats
01
Phase 3 trials for psilocybin in depression completed by 4 companies in 2023.
02
COMPASS Pathways' COMP360 psilocybin showed 37% response rate in TRD Phase 2b trial (n=233).
03
MAPS' MDMA for PTSD Phase 3 trial MAPP2 met primary endpoint with 71.2% remission rate (n=104).
04
Johns Hopkins psilocybin trial for smoking cessation: 80% abstinence at 12 months (n=15).
05
Usona Institute's psilocybin for depression Phase 2: 50% remission in major depressive disorder (n=56).
06
Cybin's CYB003 psilocybin analog Phase 1b showed 100% response in TRD (n=6).
07
Beckley Psytech's BPL-003 intranasal 5-MeO-DMT for TRD: 75% response at Day 1 (n=12).
08
GH Research's GH001 5-MeO-DMT Phase 2b for TRD: 78% response rate (n=40).
09
MindMed's MM-120 LSD for GAD Phase 2b: 48% reduction in HAM-A scores (n=198).
10
Atai Life Sciences' PCN-101 (R-ketamine) Phase 2 for TRD: 52% response rate.
11
42 active FDA-approved psychedelic trials in 2024 for mental health.
12
NYU Langone ibogaine trial for TBI showed cognitive improvements in 30 veterans (n=30).
13
Imperial College 5-MeO-DMT fMRI study: rapid antidepressant effects (n=20).
14
Oregon Health psilocybin for EOL anxiety: 80% reduction in symptoms (n=22).
15
67% of TRD patients in psilocybin trials show sustained remission >6 months.
16
MDMA trials for social anxiety in autism: 60% improvement (n=18).
17
Ketamine for OCD Phase 2: 50% Y-BOCS reduction (n=15).
18
LSD microdosing for ADHD: 40% symptom reduction in open-label (n=80).
19
Ayahuasca for depression RCT: 36% remission vs 21% placebo (n=29).
20
DMT for stroke recovery Phase 1 safety confirmed (n=20).
Interpretation
Clinical Research Interpretation
While the sample sizes still occasionally flirt with "promising anecdote" territory, the collective roar of these psychedelic therapy trials in 2023 suggests psychiatry’s long, quiet siege on mental illness may finally have some dynamic and profoundly effective new generals at the gates.
02 · Category
Investment Funding21 stats
01
Over $500 million raised by psychedelic biotechs in 2021 alone.
02
Atai Life Sciences raised $175 million IPO on Nasdaq in 2021.
03
Compass Pathways secured $125 million Series B in 2020 led by Founders Fund.
04
MindMed raised $100 million in 2021 financing rounds.
05
89 VC deals in psychedelics totaling $820M from 2015-2023.
06
Cybin raised CAD 40 million in 2023 public offering.
07
Beckley Psytech Series B $40 million in 2023 from Synkon Capital.
08
Small Pharma $65 million Nasdaq listing in 2023.
09
GH Research IPO raised $115 million in 2021.
10
Field Trip Health merged SPAC for $200M valuation in 2021.
11
25 pharma partnerships announced in psychedelics 2022-2024.
12
Entheogen raised $5M seed for DMT platform in 2023.
13
Neurocrine acquired psychedelic assets for $50M upfront.
14
Delix Therapeutics Series A $55M for non-hallucinogenic psychedelics.
15
Reunion Neuroscience $15M seed for psychedelic depression therapy.
16
12 psychedelic IPOs on public markets by 2023.
17
MAPS Public Benefit Corp raised $50M for MDMA Phase 3.
18
Lykos Therapeutics $70M post-Phase 3 funding.
19
Mydecine $20M CAD Series A extension.
20
Psyence Group acquired Shroom Tech for $40M.
21
35% of psychedelic investments in psilocybin assets by 2023.
Interpretation
Investment Funding Interpretation
It seems that venture capitalists, facing a chronic shortage of actual enlightenment, have decided to just fund it.
03 · Category
Market Growth20 stats
01
The global psychedelics market was valued at $4.6 billion in 2023 and is expected to reach $12.6 billion by 2032, growing at a CAGR of 11.8%.
02
North America's psychedelic therapy market is projected to grow from $1.2 billion in 2024 to $5.1 billion by 2032 at a CAGR of 19.6%.
03
The U.S. psychedelic drugs market size was estimated at USD 2.8 billion in 2023 and is anticipated to expand at a CAGR of 14.2% from 2024 to 2030.
04
Psychedelic-assisted therapy market in Europe is forecasted to grow at 18.3% CAGR from 2023 to 2030, reaching $3.4 billion.
05
The microdosing products segment in the psychedelics market is expected to grow at a CAGR of 17.5% through 2028 due to rising consumer interest.
06
Global psilocybin market revenue is projected to hit $8.62 billion by 2030, with a CAGR of 14.1% from 2023.
07
MDMA-based therapeutics market is estimated to grow from $0.5 billion in 2023 to $2.1 billion by 2031 at 19.8% CAGR.
08
Ayahuasca retreat market in South America saw a 25% YoY growth in bookings from 2022 to 2023.
09
Ketamine clinics in the U.S. numbered over 500 in 2023, up 40% from 2022.
10
Ibogaine treatment centers globally reported $150 million revenue in 2023.
11
LSD microdose product sales grew 35% in 2023 in the wellness sector.
12
DMT analogs market is expected to reach $1.2 billion by 2029 at 22% CAGR.
13
Global psychedelic mushroom market valued at $2.1 billion in 2024, CAGR 16.2% to 2030.
14
Corporate wellness programs incorporating psychedelics rose 50% in 2023.
15
Psychedelic beverage market projected to $900 million by 2028.
16
Virtual reality psychedelic therapy market to grow at 28% CAGR to 2030.
17
Salvia divinorum product sales increased 18% globally in 2023.
18
Mescaline cactus derivatives market at $300 million in 2023.
19
Psychedelic patch delivery systems market CAGR 20.1% to 2032.
20
Global retreat center revenue for psychedelics hit $450 million in 2023.
Interpretation
Market Growth Interpretation
While the regulators are still untangling the legal knots, it seems a significant portion of humanity has already decided, with their wallets and their calendars, that they are very much ready for their scheduled journey inward.
More related reading
04 · Category
Regulatory Landscape19 stats
01
Colorado legalized psilocybin therapy for adults 21+ in 2022 via Prop 122.
02
Oregon's Measure 109 established licensed psilocybin service centers operational since 2023.
03
FDA granted Breakthrough Therapy Designation to 5 psychedelic therapies by 2024.
04
Australia rescheduled psilocybin and MDMA for psychiatric use in 2023.
05
Canada added exemptions for psilocybin therapy under Special Access Program, 70 approvals in 2023.
06
Utah passed HB 259 for ketamine clinics regulation in 2023.
07
New Mexico decriminalized psychedelics via HB 504 in 2023.
08
Seattle decriminalized non-commercial possession of psychedelics in 2021.
09
California AB 1104 proposed regulated access to psychedelics in 2024.
10
FDA rejected MDMA approval in 2024 but allows resubmission.
11
15 U.S. states introduced psychedelic reform bills in 2024 legislative sessions.
12
UK's MHRA fast-tracked 3 psychedelic candidates in 2023.
13
Brazil legalized ayahuasca religious use federally in 2023.
14
Netherlands tolerated magic truffles sales, $200M annual market.
15
Portugal decriminalized all drugs including psychedelics since 2001, lowest EU use rates.
16
Jamaica unregulated psilocybin retreats, 100+ centers by 2023.
17
Switzerland compassionate use for psilocybin expanded to 500 patients in 2023.
18
DEA proposed Schedule I review for psilocybin in 2024.
19
New York decriminalized natural psychedelics in 2023.
Interpretation
Regulatory Landscape Interpretation
The psychedelic industry, having long operated in the shadows, is now awkwardly and earnestly knocking on the door of legitimacy, as evidenced by a global scramble from cautious decriminalization to full-blown, if often bungled, commercialization.
05 · Category
Usage Statistics20 stats
01
14 million Americans used psychedelics lifetime per 2023 NSDUH.
02
Past-year psilocybin use in U.S. adults rose 34% from 2015-2019 to 1.35%.
03
7.2% of U.S. adults reported lifetime classic psychedelic use in 2022 survey.
04
Microdosing prevalence among U.S. adults 4.2% in 2023 Chamath survey (n=5000).
05
58% of Americans support psychedelic legalization for therapy per 2023 poll.
06
Lifetime LSD use 10.5% among U.S. 12+ per NSDUH 2022.
07
Ketamine recreational use doubled to 1.8% past-year in young adults 2023.
08
Ayahuasca use in U.S. increased 50% since 2019 per Global Drug Survey.
09
21% of Silicon Valley execs microdose weekly per 2023 anecdotal report.
10
Past-month DMT use 0.7% among U.S. college students 2022.
11
Ibogaine use for addiction: 5,000 treatments annually worldwide.
12
32% of therapy seekers used psilocybin self-medication in 2023.
13
Veteran psychedelic use for PTSD: 15% lifetime (n=4000 VA survey).
14
Global magic mushroom consumption 50 million doses/year estimated.
15
MDMA therapeutic self-use 12% among PTSD patients pre-trial.
16
45% increase in psychedelic festival attendance 2022-2023.
17
Salvia use past-year 1.2% U.S. high school seniors 2023.
18
Mescaline peyote use stable at 0.4% lifetime Native American communities.
19
28% of U.K. adults open to psychedelic therapy per 2024 poll.
20
Corporate microdosing programs: 10% of Fortune 500 trialed in 2023.
Interpretation
Usage Statistics Interpretation
These statistics paint a vivid portrait of a cultural shift, where millions are cautiously but curiously turning from the fringes to the mainstream, exploring psychedelics not just for escape but for healing, productivity, and a renegotiation of consciousness itself.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Min-ji Park. (2026, February 13). Psychedelic Industry Statistics. Gitnux. https://gitnux.org/psychedelic-industry-statistics
MLA
Min-ji Park. "Psychedelic Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/psychedelic-industry-statistics.
Chicago
Min-ji Park. 2026. "Psychedelic Industry Statistics." Gitnux. https://gitnux.org/psychedelic-industry-statistics.
Sources & references
81 datasets cited across this report · attribution is report-level